Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | GNAO1 | P09471 | 5/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 4/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.35 |
| ▸ | GBA1 | P04062 | 2/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22047606 | 0.92 | NCF1 (0.42) | NCF1GNAO1HRH3HRH4ACHE | |
| SCHEMBL25565872 | 0.91 | GNAO1 (0.41) | NCF1GNAO1HRH3HRH4ACHE | |
| SCHEMBL23416766 | 0.90 | NCF1 (0.43) | NCF1GNAO1HRH3HRH4ACHE | |
| SCHEMBL25569153 | 0.90 | NCF1 (0.43) | NCF1GNAO1HRH3HRH4ACHE | |
| SCHEMBL3994450 | 0.86 | GNAO1 (0.56) | NCF1GNAO1HRH3HRH4ACHE | |
| SCHEMBL24480314 | 0.86 | NCF1 (0.41) | NCF1GNAO1HRH3HRH4ACHE | |
| SCHEMBL757866 | 0.85 | NCF1 (0.62) | NCF1GNAO1HRH3HRH4ACHE | |
| SCHEMBL18525560 | 0.84 | NCF1 (0.36) | NCF1GNAO1ACHE | |
| SCHEMBL9728002 | 0.83 | GNAO1 (0.53) | NCF1GNAO1HRH3ACHEGNAI3 | |
| SCHEMBL24881447 | 0.82 | NCF1 (0.48) | NCF1GNAO1HRH3HRH4ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024112692-A1 | CASITAS B-LINEAGE LYMPHOMA PROTOONCOGENE B (CBL-B) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| CN-117487201-A | Amphoteric ion exchange resin solution, flow battery diaphragm and all-vanadium flow battery | 国家电投集团氢能科技发展有限公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2022047145-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| US-10000472-B2 | Photochromic compounds | TRANSITIONS OPTICAL, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180051037-A1 | Photochromic Thienochromene Compounds | TRANSITIONS OPTICAL, INC. | 2018-02-22 | — | — | US | disclosed |
| US-9630902-B2 | Method of preparing fused ring indeno compounds | TRANSITIONS OPTICAL, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160333262-A1 | Photochromic Compounds | TRANSITIONS OPTICAL, INC. | 2016-11-17 | — | — | US | disclosed |
| US-20160209561-A1 | Photochromic Articles That Include Photochromic-Dichroic Materials | TRANSITIONS OPTICAL, INC. | 2016-07-21 | — | — | US | disclosed |
| US-20160168135-A1 | OXINDOLE DERIVATIVES CARRYING AN OXETANE SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-06-16 | — | — | US | disclosed |
| US-20160060205-A1 | Method Of Preparing Fused Ring Indeno Compounds | TRANSITIONS OPTICAL, INC. | 2016-03-03 | — | — | US | disclosed |
| EP-1789410-B1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2009-06-17 | — | — | EP | disclosed |
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | US | disclosed |
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | US | disclosed |
| US-20080096049-A1 | capable of switching between the two states in response to at least actinic radiation; thermally reversible | TRANSITIONS OPTICAL, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096048-A1 | Thermally reversible; absorption ratio greater than 2.3 | TRANSITIONS OPTICAL, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-7342112-B2 | Photochromic compounds | PPG INDUSTRIES OHIO, INC. (US) | 2008-03-11 | — | — | US | disclosed |
| US-20080051575-A1 | capable of switching between the two states in response to at least actinic radiation; thermally reversible | TRANSITIONS OPTICAL ,INC. (US) | 2008-02-28 | — | — | US | disclosed |
| US-20080045704-A1 | Thermally reversible; absorption ratio greater than 2.3; cell method | TRANSITIONS OPTICAL, INC. (US) | 2008-02-21 | — | — | US | disclosed |
| EP-1789410-A1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006029906-A1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | DRD2, DRD4, PNMT | NCF1 4640/4885GNAO1 3472/4885HRH3 620/4885 |
| US-20080045704-A1 | Thermally reversible; absorption ratio greater than 2.3; cell method | CCND3, CCND1, CCND2 | NCF1 3168/4885GNAO1 4027/4885HRH3 4004/4885 |
| US-20080096048-A1 | Thermally reversible; absorption ratio greater than 2.3 | CCND1, CCND3, CCND2 | NCF1 3433/4885GNAO1 3851/4885HRH3 4098/4885 |
| US-20160060205-A1 | Method Of Preparing Fused Ring Indeno Compounds | INHA, INTS9, CA9 | NCF1 3485/4885GNAO1 1534/4885HRH3 1947/4885 |
| US-20160168135-A1 | OXINDOLE DERIVATIVES CARRYING AN OXETANE SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AVPR2, AVPR1B, AVPR1A | NCF1 3909/4885GNAO1 517/4885HRH3 707/4885 |
| US-20160333262-A1 | Photochromic Compounds | CCR4, CCR8, CBR3 | NCF1 4299/4885GNAO1 509/4885HRH3 1480/4885 |
| US-20080051575-A1 | capable of switching between the two states in response to at least actinic radiation; thermally reversible | CCND1, CCND2, CCNE1 | NCF1 2485/4885GNAO1 2424/4885HRH3 4576/4885 |
| US-10000472-B2 | Photochromic compounds | CCR4, CCR8, CBR3 | NCF1 4299/4885GNAO1 509/4885HRH3 1480/4885 |
| US-20180051037-A1 | Photochromic Thienochromene Compounds | CRY1, CRY2, TERT | NCF1 2988/4885GNAO1 1027/4885HRH3 456/4885 |
| US-20080096049-A1 | capable of switching between the two states in response to at least actinic radiation; thermally reversible | CCND1, CCND2, CCNE1 | NCF1 2485/4885GNAO1 2424/4885HRH3 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.